SYNLAB Analytics & Services Germany GmbHhttps://www.synlab.de/pharma/product-analysis
CoroPrevention – Clinical Trial to evaluate personalized prevention in CHD Initiated by Prof. Prof. Dr. med. März (SYNLAB Akademie) and Prof. Dr. Laaksonen (Zora Biosciences)
Coronary heart disease (CHD) remains the leading cause of premature death worldwide. CHD affects both men and women and of all deaths before the age of 75 years in Europe, 42% in women and 38% in men are due to CHD. Thus, prevention of CHD morbidity and mortality is a major challenge in clinical medicine. Cardiovascular diseases cost the EU economy almost €294 billion a year, and are projected to rise with both the ageing population and the cost of novel treatments. European and global CHD burden remains unsustainable. Better risk stratification tools and personalized care of patients are needed for reducing morbidity and mortality of CHD and the associated economic burden.
To this end Prof. Dr. med. März (SYNLAB Akademie) and Prof. Dr. Laaksonen (Zora Biosciences) together with other leading European experts initiated the prospective clinical trial “CoroPrevention” financed by the European Union Horizon 2020 funding program.
This clinical trial will demonstrate whether in high risk CHD patients a personalized prevention program will result in decreased risk of CV event as well as the economic value of a personalized prevention program. To this aim 15.000 patients around Europe will be screened to randomize 2.000 high risk patients by a biomarker score.
We are thrilled to announce that SYNLAB Pharma will support this important and valuable clinical trial with central lab services: high quality bioanalytical sample analysis incl. state of the art methods and proven experience, clinical trial support incl. project and data management, blood collection kits, sample logistics, etc.
For further information about this clinical trial please contact us!